DK4019019T3 - Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling - Google Patents

Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling Download PDF

Info

Publication number
DK4019019T3
DK4019019T3 DK21207246.6T DK21207246T DK4019019T3 DK 4019019 T3 DK4019019 T3 DK 4019019T3 DK 21207246 T DK21207246 T DK 21207246T DK 4019019 T3 DK4019019 T3 DK 4019019T3
Authority
DK
Denmark
Prior art keywords
riluzole
analogues
cancer
products
treatment
Prior art date
Application number
DK21207246.6T
Other languages
English (en)
Inventor
Vladimir Coric
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Application granted granted Critical
Publication of DK4019019T3 publication Critical patent/DK4019019T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21207246.6T 2016-05-20 2017-05-19 Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling DK4019019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339433P 2016-05-20 2016-05-20
EP17800310.9A EP3458053B1 (en) 2016-05-20 2017-05-19 Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers

Publications (1)

Publication Number Publication Date
DK4019019T3 true DK4019019T3 (da) 2024-05-06

Family

ID=60326148

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17800310.9T DK3458053T3 (da) 2016-05-20 2017-05-19 Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling
DK21207246.6T DK4019019T3 (da) 2016-05-20 2017-05-19 Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17800310.9T DK3458053T3 (da) 2016-05-20 2017-05-19 Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling

Country Status (26)

Country Link
US (4) US12383619B2 (da)
EP (3) EP4019019B1 (da)
JP (4) JP7224186B2 (da)
KR (2) KR102525527B1 (da)
CN (2) CN109890387B (da)
AU (2) AU2017266951B2 (da)
CA (1) CA3025019A1 (da)
CY (1) CY1124999T1 (da)
DK (2) DK3458053T3 (da)
EA (1) EA201892587A1 (da)
ES (3) ES2981830T3 (da)
FI (1) FI4019019T3 (da)
HR (2) HRP20220237T1 (da)
HU (2) HUE058184T2 (da)
IL (2) IL292302B2 (da)
LT (2) LT3458053T (da)
MX (2) MX2018013868A (da)
PH (1) PH12018502409A1 (da)
PL (2) PL4019019T3 (da)
PT (2) PT4019019T (da)
RS (2) RS62935B1 (da)
SG (1) SG11201809669RA (da)
SI (2) SI4019019T1 (da)
SM (1) SMT202400174T1 (da)
WO (2) WO2017201501A1 (da)
ZA (1) ZA201807398B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US10639298B2 (en) * 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
IL292302B2 (en) * 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US20190315865A1 (en) * 2016-10-28 2019-10-17 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
TWI817952B (zh) 2017-08-25 2023-10-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
US20210177841A1 (en) * 2017-11-03 2021-06-17 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US12161633B2 (en) * 2018-07-22 2024-12-10 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
US12270054B2 (en) 2019-01-24 2025-04-08 University Of Cincinnati Autologous tumor organoid and immune cell co-cultures and methods of use as predictive models for pancreatic cancer treatment
AU2020291464A1 (en) * 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
WO2021188616A1 (en) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
KR102441650B1 (ko) * 2020-07-31 2022-09-08 서울대학교병원 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법
WO2022197767A1 (en) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for improving survival in lung cancer patients via ketamine oncoprotection
EP4373525A4 (en) * 2021-07-21 2025-05-07 Viracta Subsidiary, Inc. CANCER TREATMENT COMBINATIONS
TW202406539A (zh) * 2022-04-21 2024-02-16 大陸商北京加科思新藥研發有限公司 藥物組合及其用途
CN116492322A (zh) * 2023-05-10 2023-07-28 徐州医科大学 小分子阻滞剂mem在制备治疗肿瘤药物的应用
CN119174765A (zh) * 2024-09-04 2024-12-24 复旦大学附属中山医院 Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209066A (en) 1921-03-01 Tschirner Frederick Conversion of potassium to soluble state
US7812A (en) 1850-12-03 Nail-plate feeder and turner
US135A (en) 1837-03-03 Jesse j
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE323467T1 (de) 1997-07-25 2006-05-15 Alpex Pharma Sa Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
DE60222160T2 (de) 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
US7498414B2 (en) 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
KR101444717B1 (ko) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DK1819358T3 (da) 2004-11-18 2014-10-27 Imclone Llc Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
ES2374603T3 (es) 2005-01-06 2012-02-20 Novo Nordisk A/S Agentes de unión a kir y procedimientos de uso de los mismos.
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1744020A1 (de) 2005-07-14 2007-01-17 Siemens Aktiengesellschaft Verfahren zum Starten einer Dampfturbinenanlage
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
BRPI0619424B1 (pt) 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
SI2195017T1 (sl) 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
RU2013121744A (ru) * 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
WO2012122444A1 (en) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
HK1198133A1 (en) 2011-08-02 2015-03-13 辉瑞公司 Crizotinib for use in the treatment of cancer
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
SI2776032T1 (sl) 2011-11-09 2018-12-31 Bristol-Myers Squibb Company Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
US10864271B2 (en) * 2012-02-15 2020-12-15 Rutgers, The State University Of New Jersey Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
BR112017000497B1 (pt) * 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
US20160073759A1 (en) * 2014-09-15 2016-03-17 Beauty Solutions Agency Inc. Nail covering
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
US10235906B2 (en) * 2014-11-18 2019-03-19 Maximum Fidelity Surgical Simulations, LLC Post mortem reconstitution of circulation
US20160140879A1 (en) * 2014-11-19 2016-05-19 David Hananel Anatomically correct movement or deformation of simulated bodily structures
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
US10639298B2 (en) 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
EP3355875B1 (en) 2015-10-01 2021-09-29 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
IL292302B2 (en) * 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy

Also Published As

Publication number Publication date
SG11201809669RA (en) 2018-11-29
US20250360208A1 (en) 2025-11-27
ES2912131T3 (es) 2022-05-24
EP4019019B1 (en) 2024-02-07
JP2019516711A (ja) 2019-06-20
EA201892587A1 (ru) 2019-04-30
WO2017201502A1 (en) 2017-11-23
MX2022010377A (es) 2022-09-21
HRP20220237T1 (hr) 2022-04-29
PH12018502409A1 (en) 2019-04-08
JP7653398B2 (ja) 2025-03-28
ZA201807398B (en) 2020-05-27
LT3458053T (lt) 2022-02-25
IL292302A (en) 2022-06-01
CN109890387A (zh) 2019-06-14
US20190290619A1 (en) 2019-09-26
AU2017266951A1 (en) 2018-11-22
RS62935B1 (sr) 2022-03-31
US20230310595A1 (en) 2023-10-05
US12383619B2 (en) 2025-08-12
EP3458054A4 (en) 2019-10-02
JP2022191256A (ja) 2022-12-27
FI4019019T3 (fi) 2024-05-14
SI3458053T1 (sl) 2022-04-29
KR102525527B1 (ko) 2023-04-24
KR102369735B1 (ko) 2022-03-02
PT3458053T (pt) 2022-02-01
WO2017201501A1 (en) 2017-11-23
US20190175731A1 (en) 2019-06-13
EP3458054B1 (en) 2022-02-23
IL262849A (en) 2018-12-31
ES2905823T3 (es) 2022-04-12
RS65474B1 (sr) 2024-05-31
EP3458054A1 (en) 2019-03-27
KR20190009334A (ko) 2019-01-28
ES2981830T3 (es) 2024-10-10
CN115350263A (zh) 2022-11-18
SMT202400174T1 (it) 2024-07-09
PT4019019T (pt) 2024-05-13
AU2021221560B2 (en) 2023-10-26
IL292302B1 (en) 2023-06-01
CA3025019A1 (en) 2017-11-23
IL262849B (en) 2022-05-01
JP2019516712A (ja) 2019-06-20
AU2021221560A1 (en) 2021-09-16
JP7169195B2 (ja) 2022-11-10
BR112018073781A2 (pt) 2019-02-26
EP3458053B1 (en) 2021-12-08
JP7493569B2 (ja) 2024-05-31
HUE058184T2 (hu) 2022-07-28
AU2017266951B2 (en) 2021-05-27
SI4019019T1 (sl) 2024-07-31
CN109890387B (zh) 2022-06-14
PL3458053T3 (pl) 2022-04-25
IL292302B2 (en) 2023-10-01
LT4019019T (lt) 2024-06-25
EP3458053A4 (en) 2019-11-20
PL4019019T3 (pl) 2024-07-01
HRP20240617T1 (hr) 2024-07-19
KR20220029772A (ko) 2022-03-08
DK3458053T3 (da) 2022-02-21
HUE066655T2 (hu) 2024-08-28
EP3458053A1 (en) 2019-03-27
MX2018013868A (es) 2019-02-21
CY1124999T1 (el) 2023-01-05
EP4019019A1 (en) 2022-06-29
JP7224186B2 (ja) 2023-02-17
JP2023012508A (ja) 2023-01-25
US11400155B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
DK3458053T3 (da) Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
HUE059694T2 (hu) Készítmény rák kezelésére
IL264143B (en) Processes for preparing olaparib
IL251526B (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HUE059158T2 (hu) Eljárás pridopidin elõállítására
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
HUE058257T2 (hu) Eljárások oxatiazin-jellegû vegyületek elõállítására
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
IL259669B (en) Combination products for the treatment of rsv
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
FI20155881A (fi) Menetelmä säteilyikkunan valmistamiseksi ja säteilyikkuna
IL258137B1 (en) HIV treatment measures
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
HUE045746T2 (hu) Eljárás fûszerkészítmények elõállítására
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome